BMJ reports retatrutide trial weight loss of up to 25%
Eli Lilly's triple-acting GIP, GLP-1 and glucagon receptor agonist outpaced the reductions reported for currently marketed incretin drugs.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 30 20:00 ETSource: BMJ (Clinical research ed.)
The wire
- 01The BMJ reports trial results for retatrutide, a triple-receptor agonist injection, showing weight loss of up to 25% in treated participants.
- 02Prescribers and telehealth operators tracking the incretin pipeline should expect patient questions about how retatrutide compares with semaglutide and tirzepatide.
- 03Retatrutide is not approved; full peer-reviewed trial detail on dosing, tolerability and durability is needed before any clinical positioning.
From the source
Read at pubmed.ncbi.nlm.nih.govRetatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest
BMJ (Clinical research ed.) · 2026 Oct 1 · Wise J et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42823062/
